Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Golimumab
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 30 Mar 2023 Results of Post Hoc Analyses from NCT03162796, NCT0315828, NCT02437162, and NCT02438787 , published in the Advances in Therapy
- 14 Nov 2022 Results assessing the genetic and molecular distinctions between axial psoriatic arthritis and ankylosing spondylitis in the patients from NCT03162796/NCT0315828 and NCT02437162/NCT02438787 studies presented at the ACR Convergence 2022
- 04 Jun 2022 Blood and serum samples were collected from consenting patients in the NCT03162796/NCT0315828 studies of guselkumab in PsA and the NCT02437162/NCT02438787 studies of ustekinumab in AS presented at the 23rd Annual Congress of the European League Against Rheumatism